Mikkel Holm Vendelbo

Mikkel Holm Vendelbo is a Danish physician and researcher who operates a professional medical practice and serves as an Associate Professor at Aarhus University and Aarhus University Hospital. His expertise lies in nuclear medicine and PET imaging, where he focuses on the development and clinical validation of novel radiopharmaceuticals for diagnosing and monitoring diseases. He has acted as a sponsor and principal investigator for clinical trials involving tracers such as 16α-18F-fluor-17β-estradiol (FES) for estrogen receptor-positive cancers and 64Cu for Wilson disease. His research also encompasses the study of biomarkers for prostate cancer and the physiological mechanisms of insulin resistance and autophagy.